Key clinical point: RSLV-132 is a promising therapy that warrants further investigation for improving the symptoms of fatigue in patients with primary Sjögren’s syndrome (pSS).
Major finding: The mental component of PRO-F improved by 1.53 points among the patients given RSLV-132, while there was a worsening of 0.06 points in the placebo group (P = .046).
Study details: A randomized, phase 2, double-blind, placebo-controlled, proof of concept RESOLVE study involving 30 patients with pSS.
Disclosures: The trial was sponsored by Resolve Therapeutics. Dr. Ng was an investigator in the trial.
Fisher B et al. Ann Rheum Dis. 2019 Jun;78(Suppl 2):177, Abstract OP0202. doi: 10.1136/annrheumdis-2019-eular.3098